Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231 cells

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1407-1412

  Stuart, Emma C ^a   Larsen, Lesley ^b   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

Author keywords

Apoptosis; Epigallocatechin gallate; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; TAMOXIFEN;

EID: 34447260039     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1407     Document Type: Article

References (40)

1. Sarkar FH and Li Y: Using chemopreventative agents to enhance the efficacy of cancer therapy. Cancer Res 66: 3347-3350, 2006.
2. Blagosklonny MV: Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol Sci 26: 77-81, 2005. (Pubitemid 40170169)
3. Chisholm K, Bray BJ and Rosengren RJ: Tamoxifen and epigallocatechin gallate (EGCG) are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anti-Cancer Drugs 15: 889-897, 2004.
4. Tanos V, Brzezinski A, Drize O, Strauss N and Peretz T: Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 102: 188-194, 2002.
5. Shen F, Xue X and Weber G: Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res 19: 1657-1662, 1999. (Pubitemid 29392719)
6. Guthrie N, Gapor A, Chambers AF and Carroll KK: Inhibition of proliferation of estrogen receptor negative MDA-MB-435 and positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127: 544S-548S, 1997.
7. Ferlini C, Scambia G, Distefano M, et al: Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 75: 884-891, 1997.
8. El Etreby MF, Liang Y, Wrenn RW and Schoenlein PV: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51: 149-168, 1998. (Pubitemid 28561420)
9. Bollig A, Du Q-Q, Fan S-T, Yu B, Sarkar FH and Liao J: Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonists and cooperative effects on cytotoxicity in human mammary carcinoma cells. Oncol Rep 14: 177-183, 2005.
10. Shen F and Weber G: Tamoxifen downregulates signal transduction and is synergistic with tiazofurin in human breast carcinoma MDA-MB-435 cells. Oncol Res 10: 325-331, 1998. (Pubitemid 128736329)
11. McDougal A, Wormke M, Calvin J and Safe S: Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 61: 3902-3907, 2001.
12. Mandlekar S, Yu R, Tan T-H and Kong A-NT: Activation of caspase-3 and c-jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000, 2000.
13. Ferlini C, Scambia G, Marone M, et al: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79: 257-263, 1999.
14. Ahmad N, Feyes DK, Nieminen AL, Agarwal R and Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89: 1881-1886, 1997.
15. Chen ZP, Schell JB, Ho CT and Chen KY: Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 129: 173-179, 1998.
16. Gupta S, Ahmad N, Nieminen A and Mukhtar H: Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 164: 82-90, 2000.
17. Leone M, Zhai D, Sareth S, Kitada S, Reed JC and Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 63: 8118-8121, 2003. (Pubitemid 37549456)
18. Morre DJ, Bridge A, Wu L-W and Morre DM: Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth transformed cells in culture. Biochem Pharmacol 60: 937-946, 2000.
19. Piskula MK and Terao J: Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. J Nutr 128: 1172-1178, 1998.
20. Lu H, Meng X and Yang CS: Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 31: 572-579, 2003.
21. Nishiyama T, Ogura K, Nakano H, et al: Reverse geometrical selectivity in glucuronidation and sulfation of cis and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63: 1817-1830, 2002.
22. Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
23. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
24. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere J-L, Petit PX and Kroemer G: Reduction in mitochondrial potential constitutes an early irreversible step of programmed important death in vivo. J Exp Med 181: 1661-1672, 1995.
25. Fowler BA, Kleinow KM, Squibb KS, Lucier GW and Hayes AW: Organelles as tools in toxicology. In: Principles and Methods of Toxicology. Hayes AW (ed). Ravens Press Ltd., New York, pp1201-1230, 1994.
26. Bray BJ, Perry NB, Menkes DB and Rosengren RJ: St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 66: 27-33, 2002.
27. Kivits GAA, van der Sman FJP and Tijburg LBM: Analysis of catechins from green and black tea in humans: a specific and sensitive colorimetric assay of total catechins in biological fluids. Int J Food Sci Nutr 48: 387-392, 1997.
28. Meng X, Sang S, Zhu N, et al: Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem Res Toxicol 15: 1042-1050, 2002.
29. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E and Fujiki H: Synergistic effects of (-)epigallocatehin gallate with (-)-epicatechin, sulindac or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59: 44-47, 1999. (Pubitemid 29062952)
30. Rosengren RJ: Catechins and the treatment of breast cancer: Possible utility and mechanistic targets. Drugs 6: 1073-1078, 2003.
31. Lambert JD, Hong J, Kim DH, Mishin VM and Yang CS: Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J Nutr 134: 1948-1952, 2004.
32. Suzuki M, Yoshino K, Maeda-Yamamoto M, Miyase T and Sano M: Inhibitory effects of tea catechins and O-methylated derivatives of (-)-epigallocatechin-3- O-gallate on mouse type IV allergy. J Agric Food Chem 48: 5649-5653, 2000.
33. Tachibana T, Sunada Y, Miyase T, Sano M, Maeda-Yamamoto M and Yamada K: Identification of a methylated tea catechin as an inhibitor of degranulation in human basophilic KU812 cells. Biosci Biotechnol Biochem 64: 452-454, 2000.
34. Gartel AL, Felicianok C and Tyner AL: A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 13: 405-408, 2003.
35. Chen C, Shen G, Hebbar V, Hu R, Owuor ED and Kong A-NT: Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 24: 1369-1378, 2003.
36. Gupta S, Hastak K, Afaq F, Ahmad N and Mukhtar H: Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis. Oncogene 23: 2507-2522, 2004.
37. Mabuchi S, Ohmichi M, Kimura A, et al: Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cells lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 145: 1302-1313, 2004.
38. Vayalil PK and Katiyar SK: Treatment of epigallocatechin-3-gallate inhibits matrix metalloprotineases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappa B in human prostate carcinoma DU-145 cells. Prostate 59: 33-42, 2004.
39. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15: 885-890, 2004.
40. Cui Y, Parra I, Zhang M, et al: Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66: 5950-5959, 2006.